JAMA Oncology,
This cost-effectiveness microsimulation modeling study estimates incremental lifetime effects, costs, and cost-effectiveness of…
This cost-effectiveness microsimulation modeling study estimates incremental lifetime effects, costs, and cost-effectiveness of…
This cost-effectiveness microsimulation modeling study of 11,836 women, compared testing for BRCA1/BRCA2/PALB2 in unselected…
This cost-effectiveness microsimulation modeling study estimates incremental lifetime effects, costs, and cost-effectiveness of…
Estudios multigenes para todos los pacientes de cáncer de mama. https://jamanetwork.com/journals/jamaoncology/fullarticle/275237…
Southampton researchers, led by Professor Diana Eccles, have been involved in an international study that shows offering multi-ge…
Southampton researchers, led by Professor Diana Eccles, have been involved in an international study that shows offering multi-ge…
High-Risk Multigene Test in Breast Ca Deemed Cost Effective: But workforce readiness and potential for harm remain concerns
Multigene testing for all US and UK breast cancer patients is cost-effective, suggesting this should be offered to all women…
家族歴やガイドラインに従って乳がん患者の遺伝子検査を行うより、全乳がん患者で BRCA1 / BRCA2 / PALB2 多遺伝子変異検査を実施する方が費用対効率に優れ、1年間の乳がんおよび卵巣がん死を英国では633例、米国では2,406例減らす (文献20…
👉A partir de octubre (Mes de concientización sobre el cáncer de mama), Rodrigo Arrangoiz MS, MD, miembro de FACS de la Sociedad…
This cost-effectiveness microsimulation modeling study of 11,836 women, compared testing for BRCA1/BRCA2/PALB2 in unselected…